louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00454064: Cognitive-behavioural Treatment of Chronic Back Pain
Official title: Study to Compare a Cognitive-behavioral Treatment With a Cognitive-behavioral Treatment With Biofeedback Elements to Patients With Chronic (Low) Back Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Back Pain
Keywords: cognitive-behavioral therapy
back pain
low back pain
biofeedback
randomized controlled study
EMG biofeedback
Lead sponsor: Philipps University Marburg
Sponsor class: OTHER
First posted: 2007-03-29
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study:

* to compare two cognitive-behavioral treatments

Detailed description: 128 patients suffering from chronic back pain were randomly assigned to either Wait List Control, Cognitive Behavioral Treatment or Cognitive Behavioral Treatment and Biofeedback.

Measures were conducted 6 months before treatment (Wait List Control) immediately before and after treatment and at 6-months follow-up.

25 weekly 1-hr sessions of individualized outpatient cognitive behavioral treatment of chronic back pain

Treatment elements:

Cognitive treatment: identification, evaluation and correction of dysfunctional beliefs about themselves and pain by cognitive restructuring, problem-solving training and coping skills training

Behavioural treatment: increasing activity levels (sports, social activities, work), reducing medication intake and unnecessary health care utilization Relaxation training: progressive muscle relaxation, biofeedback.

Eligibility criteria: Inclusion Criteria:

* Back pain since 6 months

Exclusion Criteria:

* Patients with psychosis, borderline psychopathy, drug dependence i.e. alcohol

Primary outcomes:
measure: pain intensity
timeFrame: start of treatment, end of treatment, 6-months follow-up
Secondary outcomes:
measure: pain disability
timeFrame: start of treatment, end of treatment, 6-months follow-up
measure: depression
timeFrame: start of treatment, end of treatment, 6-months folow-up
Other outcomes:
Locations:
city: Marburg
country: Germany
facility: University Marburg, Department of Clinical Psychology and Psychotherapy
state: Hessen
Study officials:
affiliation: University Marburg, Department of Clinical Psychology and Psychotherapy
name: Winfried Rief, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT02999490: 18F-FDG PET/CT in Diagnostic Patients of Disorder of Consciousness
Official title: 18F-FDG PET/CT in Diagnostic Patients of Disorder of Consciousness
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Persistent Vegetative State
Lead sponsor: Guangzhou General Hospital of Guangzhou Military Command
Sponsor class: OTHER
First posted: 2016-12-21
Enrollment: 20
Sex: ALL
Minimum age (years): 10
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Clinical examinations are difficult to discriminate between vegetative state and minimally conscious state. the diagnostic and prognostic usefulness of neuroimaging methods has not been established in a clinical setting. we will do a forward study of PET imaging in disorders of consciousness patients, and validate with clinical assessments with the coma recovery Scale-Revised(CRS-R).

Detailed description: Every patient need to be conducted the PET/CT scanning two times.The first time is resting state.The second time is stimulated state by watching a vedio.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of disorder of consciousness

Exclusion Criteria:

-

Primary outcomes:
measure: standardized uptake value
timeFrame: 60 mins after injecting 18F-FDG
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: The PET/CT Centre Guangzhou General Hospital of Guangzhou Military Command
state: Guangdong
Study officials:
name: Yin Jilin
role: STUDY_DIRECTOR
References:
Clinical trial NCT00941590: Postencephalitic Symptoms After Tick Borne Encephalitis
Official title: Postencephalitic Symptoms After Tick Borne Encephalitis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Central European Encephalitis
Keywords: tick borne encephalitis
clinical outcome
postencephalitic symptoms
Lead sponsor: University Medical Centre Ljubljana
Sponsor class: OTHER
First posted: 2009-07-17
Enrollment: 200
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with tick borne encephalitis

Brief summary: The purpose of this study is to assess clinical outcome in patients with tick borne encephalitis.


Eligibility criteria: Inclusion Criteria:

* serologically proved tick borne encephalitis in patients \> 15 years

Exclusion Criteria:

* pregnancy

Primary outcomes:
measure: Objective sequelae and subjective symptoms in patients after tick borne encephalitis.
timeFrame: 1 year follow-up.
Secondary outcomes:
measure: Comparison of subjective symptoms between patients after tick borne encephalitis and control subjects without a history of tick borne encephalitis.
timeFrame: 1 year follow-up.
Other outcomes:
Locations:
city: Ljubljana
country: Slovenia
facility: UMC Ljubljana, Department of Infectious Diseases
Study officials:
affiliation: UMC Ljubljana
name: Franc Strle, MD PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06050590: NeuroGlove PTSD Study
Official title: Impact of Peripheral Sensory Stimulation of the Hand and Synchronized Deep Breathing in the Treatment of Post-Traumatic Stress Disorder: Assessing Safety and Effectiveness
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: PTSD
Post Traumatic Stress Disorder
Keywords: PTSD
Post Traumatic Stress Disorder
Lead sponsor: NeuroGlove LLC
Sponsor class: INDUSTRY
First posted: 2023-09-22
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: NeuroGlove
Primary purpose: TREATMENT

Brief summary: This is a prospective, home-based, interventional clinical study in which 6 subjects will be enrolled. Six (6) subjects who suffer from post-traumatic stress disorder will receive treatment using the NeuroGlove.

Detailed description: This is a prospective, home-based, interventional clinical study in which 6 subjects will be enrolled. Six (6) subjects who suffer from post-traumatic stress disorder will receive treatment using the NeuroGlove.

There will be a single cohort in the study consisting of the subjects with PTSD who will receive treatment with NeuroGlove.

The trial is intended to evaluate the impact of the device use on active PTSD symptoms and subject sense of well-being.

Eligibility criteria: Inclusion Criteria:

* Able to and willing to provide informed consent. Legally authorized representatives (LARs) will not be allowed to consent on behalf of the subject.
* Men and women ≥18 and \<85 years of age.
* Carry an active diagnosis of PTSD.
* Suffer from PTSD symptoms that impact subject's daily activities and quality of life.

Exclusion Criteria:

* Physical limitations of the upper extremity (e.g., fracture, joint deformity, severe spasticity/contracture, wounds, skin breakdown, lymphedema, etc.)
* Subject lacks the ability to comprehend or following instructions, or for any reason, in the opinion of the investigator, would be unlikely or unable to comply with study protocol requirements.
* Currently participating in another interventional clinical trial. (Observational clinical trial participation is allowed for study enrollment.)

Primary outcomes:
measure: PTSD Symptom Reduction
timeFrame: 4 weeks
measure: Portion of participants with adverse events
timeFrame: 4 weeks
Secondary outcomes:
measure: PTSD Symptom Severity
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Saint Paul
country: United States
facility: NeuroGlove
state: Minnesota
Study officials:
affiliation: NeuroGlove LLC
name: Eric Nussbaum, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05157490: Preoperative Mindfulness: Minimally Invasive Hysterectomy
Official title: Preoperative Mindfulness Training for Minimally Invasive Hysterectomy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pain, Postoperative
Lead sponsor: Montefiore Medical Center
Sponsor class: OTHER
Collaborators: name: Howard University
name: Headspace Meditation Limited
First posted: 2021-12-15
Enrollment: 72
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is a randomized control trial investigating the effects of a preoperative mindfulness intervention on postoperative pain, quality of recovery and stress scores in women undergoing minimally invasive hysterectomy. The mindfulness intervention will be delivered via the application Headspace™. The primary outcome will be pain scores measured on postoperative day one. Secondary outcomes will include quality of recovery scores and perceived stress scores measured on postoperative days 1 and 7, amount of opioid consumed, and dose response between number of sessions and/or numbers of minutes of meditation performed on pain and quality of recovery scores. The study team hypothesizes that mindfulness practiced in the form of meditation delivered via an internet application will lead to reduced pain scores on postoperative day 1.


Eligibility criteria: Inclusion Criteria:

* Undergo minimally invasive hysterectomy
* Fluency in English
* Access to a device capable of running the Headspace application (smart phone or computer)

Exclusion Criteria:

* Minors
* Inability to access Headspace app
* Inability to complete surveys in English

Primary outcomes:
measure: Pain score
timeFrame: 1 day
Secondary outcomes:
measure: QOR-15 score
timeFrame: 7 days
measure: PSS-10 score
timeFrame: 7 days
measure: Opioid consumption
timeFrame: 7 days
Other outcomes:
Locations:
city: Bronx
country: United States
facility: Montefiore Medical Center-Albert Einstein College of Medicine
state: New York
Study officials:
affiliation: Montefiore Medical Center
name: Kari M Plewniak, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00743990: Effect of Effect of a Medicated Topical Therapy , Petrolatum, and No Treatment on Nocturnal Cough
Official title: Effect of a Medicated Topical Therapy, Petrolatum, and No Treatment on Nocturnal Cough and Congestion for Children With Upper Respiratory Infections
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiratory Tract Diseases
Keywords: Cough symptoms
Cold symptoms
Congestion
Children
URI
Alternative cough symptom treatment
Lead sponsor: Penn State University
Sponsor class: OTHER
Collaborators: name: Procter and Gamble
First posted: 2008-08-29
Enrollment: 143
Sex: ALL
Minimum age (years): 2
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study seeks to subjectively evaluate whether a single application of Vicks® VapoRub® (VVR) ointment or a control ointment (petrolatum) will be superior to no treatment for control of nocturnal cough and congestion due to upper respiratory tract infection (URI) as rated by both parents and children.


Eligibility criteria: Inclusion Criteria:

* Cough and congestion attributed to upper respiratory tract infection

Exclusion Criteria:

* Children with signs or symptoms of more serious or treatable disease
* Presence of itchy, watery eyes or frequent sneezing
* Tachypnea (respiratory rate \>95%ile) or labored breathing
* Symptoms for 8 or more days
* History of asthma in the past 2 years, chronic lung disease, or seizure disorder
* History of an allergic reaction to camphor, menthol, eucalyptus, petrolatum, cedarleaf oil, nutmeg oil, thymol, turpentine oil, Over-the-counter medication containing VVR components

Primary outcomes:
measure: Subjective assessment of cough and congestion symptoms
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Hershey
country: United States
facility: Penn State Milton S. Hershey Medical Center
state: Pennsylvania
Study officials:
affiliation: Penn State University
name: Ian M Paul, MD, MSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Paul IM, Beiler JS, King TS, Clapp ER, Vallati J, Berlin CM Jr. Vapor rub, petrolatum, and no treatment for children with nocturnal cough and cold symptoms. Pediatrics. 2010 Dec;126(6):1092-9. doi: 10.1542/peds.2010-1601. Epub 2010 Nov 8.
Clinical trial NCT04875390: Erector Spina Plane (ESP) Block in Pediatric Patients
Official title: Evaluation of the Effect of Ultrasonographic Guided Erector Spina Plan Block Application on Postoperative Analgesia in Infants Undergoing Laparotomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Postoperative Pain
Keywords: erector spina plane block
pediatric patient
Lead sponsor: Ankara City Hospital Bilkent
Sponsor class: OTHER
First posted: 2021-05-06
Enrollment: 40
Sex: ALL
Minimum age (years): 1
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: In this study, we aimed to evaluate the erector spina plane (ESP) block method that we used in our clinic with ultrasonography in pediatric cases between 1 month and 2 years of age who underwent laparotomy.

Detailed description: 36 patients who will undergo laparotomy between the ages of 1 month and 2 years in ASA ( American Society of Anesthesiologists) I-II class will be included in the study. patients will be divided into 2 groups. Intraoperative erector spina plane block will be applied to the 1st group (group E) and intraoperative local anesthetic infiltration will be applied to the 2nd group (group L). Postoperative pain will be evaluated with the FLACC (face, legs, activity, crying, consolation) scale.

Eligibility criteria: Inclusion Criteria:

* 1 month and 2 years of age
* ASA (American Society of Anesthesiologists) I-II class
* Patients who underwent nephrectomy, pyeloplasty, adrenal tumor excision with unilateral paramedian incision

Exclusion Criteria:

* Patients who underwent laparotomy with a midline incision
* Local infection at the injection site,
* Anatomical anomalies
* Allergies to local anesthetics,
* Coagulopathy,
* Liver, kidney failure patients

Primary outcomes:
measure: the 6th hour pediatric pain scale, face ,legs , activity; cry;consolability (FLACC)
timeFrame: 6th hour
Secondary outcomes:
measure: paracetamol consumption
timeFrame: 24 hours
Other outcomes:
Locations:
city: Çankaya
country: Turkey
facility: hülya KAŞIKARA
state: Ankara
Study officials:
affiliation: Ankara City Hospital Bilkent
name: Hülya Kaşıkara
role: PRINCIPAL_INVESTIGATOR
affiliation: Ankara City Hospital Bilkent
name: Sengül Özmert
role: STUDY_DIRECTOR
affiliation: Ankara City Hospital Bilkent
name: Feyza Sever
role: STUDY_DIRECTOR
affiliation: Yıldırım Beyazıt University Medical Pharmacology
name: Halil Kara
role: STUDY_DIRECTOR
References:
citation: Mostafa SF, Abdelghany MS, Abdelraheem TM, Abu Elyazed MM. Ultrasound-guided erector spinae plane block for postoperative analgesia in pediatric patients undergoing splenectomy: A prospective randomized controlled trial. Paediatr Anaesth. 2019 Dec;29(12):1201-1207. doi: 10.1111/pan.13758. Epub 2019 Nov 8.
citation: Aksu C, Sen MC, Akay MA, Baydemir C, Gurkan Y. Erector Spinae Plane Block vs Quadratus Lumborum Block for pediatric lower abdominal surgery: A double blinded, prospective, and randomized trial. J Clin Anesth. 2019 Nov;57:24-28. doi: 10.1016/j.jclinane.2019.03.006. Epub 2019 Mar 6.
Clinical trial NCT06839690: Comparison of Sub-maximal Voluntary Isometric Training vs Eccentric Training in Management of De Quervain Tenosynovitis
Official title: Comparison of Sub-maximal Voluntary Isometric Training vs Eccentric Training in Management of De Quervain Tenosynovitis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: De Quervain Syndrome
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2025-02-21
Enrollment: 58
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized Control Trial
Primary purpose: TREATMENT

Brief summary: This study is a randomised control trial and the purpose of this study is to compare the effects of Sub-maximal Voluntary Isometric Training vs Eccentric Training in Management of De Quervain Tenosynovitis

Detailed description: Participants will be recruited into their respective groups using a coin toss method. De Quervain Tenosynovitis will be assessed using the following tests:

1. Wrist hyperflexion and abduction of thumb (WHAT) test
2. Finkelstein's / Eichhoff's test
3. De Quervain Screening Tool

Eligibility criteria: Inclusion Criteria:

* Patients having history of pain, tenderness in thumb region from 3 weeks or more
* Age 21-50
* Both genders
* Individuals meeting the diagnostic criteria i.e.
* A score of 3 or more out of 7 on De Quervain screening tool.
* Positive Wrist hyperflexion and abduction of thumb (WHAT) test
* Positive Finkelstein's / Eichhoff's test

Exclusion criteria:

* Diagnosed cases of Osteoarthritis of 1st CMC joint and Rheumatoid arthritis
* C6 cervical radiculopathy
* Any systemic inflammatory condition like septic arthritis
* Carpal Tunnel Syndrome
* Complex regional pain syndrome
* Previous surgery impacting the first extensor compartment of the wrist
* Corticosteroid injection in the radial wrist region within 3 months of enrolment into the study
* If patient had undergone isometric thumb exercises or any strengthening protocol lasting greater than 2 weeks for the management of their current episode of de Quervain's syndrome

Primary outcomes:
measure: Grip Strength measurement
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Foundation University College of Physcial Therapy
state: Punjab
Study officials:
References:
Clinical trial NCT05275790: Efficacy of Electrical Vestibular Nerve Stimulation (VeNS) in the Management of Obesity: A Randomized Clinical Trial
Official title: Electrical Vestibular Nerve Stimulation (VeNS) Together With a Lifestyle Modification Program, Compared to a Sham Control With a Lifestyle Modification Program, as a Means of Reducing Excess Body Weight.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Lead sponsor: Neurovalens Ltd.
Sponsor class: INDUSTRY
Collaborators: name: RD Gardi Medical College
First posted: 2022-03-11
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Bilateral electrical vestibular nerve stimulation will be administered using a battery-powered vestibular nerve stimulator (ML 1000). Participants will act as their own self-control.
Primary purpose: TREATMENT

Brief summary: The aim of this study is to observe the efficacy of electrical vestibular nerve stimulation in the management of obesity.

Allocation: Active device (participants act as their own self-control) Endpoint classification: Efficacy Study. The study provides further evidence for the efficacy of electrical vestibular nerve stimulation in the management of obesity.


Eligibility criteria: Inclusion Criteria:

* BMI 30 to 40 kg/m2
* Aged above 18 years

Exclusion Criteria:

* Current use of any medications or therapy including use of oral contraceptives
* Use of dietary supplements known to affect the BMI
* Ear problems (assessed during physical examination)
* Any severe complications
* Unwilling participants

Primary outcomes:
measure: Lipid profile
timeFrame: 12 weeks
Secondary outcomes:
measure: Liver function tests
timeFrame: 12 weeks
measure: Complete blood count
timeFrame: 12 weeks
measure: Glycated hemoglobin
timeFrame: 12 weeks
measure: Mean blood glucose
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Ujjain
country: India
facility: RD Gardi Medical College
state: Madhya Pradesh
Study officials:
affiliation: RD Gardi Medical College, Ujjain
name: Dr Sai Sailesh Kumar Goothy
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03516890: Management of Spontaneous Ruptured Hepatocellular Carcinoma
Official title: Management of Spontaneous Ruptured Hepatocellular Carcinoma - Partial Hepatectomy and Prognosis: A Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rupture, Spontaneous
Rupture Liver
Hepatocellular Carcinoma
Keywords: Partial hepatectomy
Emergency
Staged
Peritoneal dissemination
Propensity score matching
Lead sponsor: Huazhong University of Science and Technology
Sponsor class: OTHER
First posted: 2018-05-04
Enrollment: 216
Sex: ALL
Minimum age (years): 15
Maximum age (years): 76
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: From January 2005 to June 2015, all patients complied with the criteria mentioned above who received partial hepatectomy or non-surgical at our center were included in this study.

Brief summary: To investigate the best treatment for hepatocellular carcinoma rupture

Detailed description: To investigate the best treatment for hepatocellular carcinoma rupture, transcatheter arterial embolization or partial hepatectomy. Furthermore, to discuss the choice of emergency or staged hepatectomy.

Eligibility criteria: Inclusion Criteria:

* Being diagnosed as hepatocellular carcinoma with tumor rupture; with complete data and without loss of follow-up

Exclusion Criteria:

* Without complete data; with loss of follow-up; not hepatocellular carcinoma based on pathological diagnosis

Primary outcomes:
measure: Overall survival of all patients
timeFrame: 5 years
Secondary outcomes:
measure: Postoperative peritoneal dissemination
timeFrame: 5 years
measure: Recurrence-free survival of all patients
timeFrame: 5 years
measure: Overall survival of partial hepatectomy patients
timeFrame: 5 years
measure: Recurrence-free survival of partial hepatectomy patients
timeFrame: 5 years
measure: Overall survival of staged partial hepatectomy patients
timeFrame: 5 years
measure: Recurrence-free of staged partial hepatectomy patients
timeFrame: 5 years
Other outcomes:
Locations:
Study officials:
affiliation: Huazhong University of Science and Technology
name: Xiao-ping Chen, PHD
role: STUDY_CHAIR
References: